ASH 2023 | Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, summarizes the findings of the randomized, double-blind Phase III MANIFEST-2 study (NCT04603495). The trial compared the bromodomain and extra terminal (BET) protein inhibitor pelabresib plus ruxolitinib to ruxolitinib plus placebo in patients with treatment-naïve myelofibrosis (MF). Results of the trial were positive in both intermediate- and high-risk patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Membership on an entity’s Board of Directors or advisory committees: Bristol Myers Squibb, Celgene, Constellation Pharmaceuticals/MorphoSys, CTI BioPharma, Galecto, Geron, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, PharmaEssentia, Prelude Therapeutics, Pfizer, Merck, Roche, AbbVie, Kartos; Research Funding: AbbVie, Bristol Myers Squibb, Celgene, Constellation Pharmac, CTI BioPharma, Geron, Incyte Corporation, Novartis, Janssen, Kartos Therapeutics, Merck, PharmaEssentia, Roche; Consultancy: Incyte, Novartis, Roche, Geron, GSK, Celgene/BMS, Kartos, AbbVie, Karyopharm, PharmaEssentia, Galecto, Imago, Sierra Oncology, Pfizer, MorphoSys, CTI Bio, AbbVie, Merck; Honoraria: GSK.
